Acomplia, a trade name of the drug rimonabant and wonder, is another drug outside of the previous line controller obesity. Acomplia was French pharmaceutical companies, Sanofi Synthelabo and is marketed by Sanofi Aventis in the world. The company makes, for the weight of people who, by excessive blocking their Lusting feel toward food. Overweight people have disadvantages other diseases such as cardiovascular problems, diabetes type II, palpitations and walks upon extra fatigue, so that Acomplia is said to minimize these problems, while hotel on patients.

Respect from an obese is about the desire of food than usual, and it leads to increased weight. Because eaters gain weight, problems related to obesity begins and the body starts free invitation at other times the effects on different diseases and problems. Acomplia is another product in the line of the Jubilee of obesity. In fact, or endogenous cannabinoids CB1 receptors are often-mentioned place pleasure centers and exciting, if it can lead to increased appetite. Rimonabant molecule in the body works by blocking CB1 cannabinoid receptor in response to the impulse to seek food. Thus, the activity is interrupted desire and the need for more demand for food by the body to stop immediately. This also makes visit to the stomach remainder of the excess food processing, so that the metabolic relaxation. Effectiveness of these entries fresh meat for adjusting the eatable man-made to control and manage their body weight.